BioCentury
ARTICLE | Company News

Aposense, Ion Beam Applications deal

September 28, 2009 7:00 AM UTC

The companies expanded a 2008 deal, giving Ion exclusive, worldwide rights to co-develop and co-commercialize the radiolabeled formulation of Aposense's [18F]-ML-10. The companies will jointly fund Ph...